# Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

> **NCT05364840** · PHASE1 · COMPLETED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 58 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** STI-1558
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05364840
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-07
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-11-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364840, "Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05364840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*